Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New medtech use evaluation in Germany:

This article was originally published in Clinica

Executive Summary

A report on German hospital service provision, "Service im Krankenhaus - Quo Vadis?", has been published by the German industry association Spectaris, in association with the Droege & Comp consultancy. The study, previewed at Medica 2004 and launched in January 2005, evaluates hospitals' use of services and products provided by medical technology companies, and assesses outsourcing trends with particular reference to the effects on those companies. Despite the tighter economic climate in Germany, the report says that there is much scope for well-targeted sales growth- and profitability-oriented businesses to thrive. Non-Spectaris members are charged Euros100 ($127) for the report. Details from Harald Hartmann at the Berlin-based association, on tel: +49 30 41 40 21 19; email: [email protected]

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT054259

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel